Tirzepatide (30 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Tirzepatide (research code LY3298176) is a single-molecule dual agonist studied for its activity at both the GLP-1 and GIP incretin receptors. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published trials, not a recommendation for use in humans or animals.

For a 30 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of 10 mg/mL (10,000 mcg/mL). At that concentration, every 1 unit drawn on a U-100 insulin syringe equals 0.01 mL and delivers 100 mcg of material, so 25 units corresponds to 2.5 mg — keeping the arithmetic clean across the titration steps.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow dose-escalation arms used across the clinical program, where the weekly amount was stepped up roughly every four weeks to manage gastrointestinal tolerability.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet, to avoid foaming.
3. Swirl or roll gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (10 mg/mL) and the reconstitution date.
5. Store upright under refrigeration at 2–8 °C, protected from light, and draw subsequent volumes with a fresh sterile syringe each time. Use within about 28 days.

Advanced (Aggressive) Titration Schedule

The advanced schedule continues past the 10 mg maintenance band to the 12.5 mg and 15 mg ceilings evaluated in the trial program, where the highest cohorts recorded the largest average weight reductions. It is held in reserve for subsequent phases only when the prior step is well tolerated.

Supplies Needed

• Tirzepatide vials (30 mg): ~2 vials for a 16-week gradual run to 10 mg; ~4 vials for a 16-week run that reaches and holds the 10 mg band; more for extended aggressive schedules at 12.5–15 mg.
• Insulin syringes (U-100, 1 mL): 16 for a 16-week schedule, with extra syringes for high-band steps that require split draws (one fresh syringe per draw).
• Bacteriostatic water (10 mL): one bottle covers ~3 vials of reconstitution; keep a second bottle for longer runs.
• Alcohol swabs: a single 100-count box comfortably covers a 16–24 week schedule.

Protocol Overview

• Research goal: model metabolic glucose regulation and weight reduction via simultaneous GLP-1 and GIP receptor activation.
• Schedule: once-weekly subcutaneous administration in the published model.
• Dose band: 2.5–10 mg standard, up to 15 mg in aggressive arms.
• Fill: 30 mg lyophilized, reconstituted to 10 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 2.5 mg step and hold each level for about four weeks before escalating.
• Keep administration on a fixed weekly cadence and the same day where possible for steady exposure modelling.
• Escalate only after tolerability is established at the prior step.
• Target the 5–10 mg band for the bulk of the published efficacy signal before considering the high-dose ceiling.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and do not freeze; use within about 28 days. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• Split larger volumes if they exceed a single syringe's capacity, as at the 12.5–15 mg steps.
• Document each draw — date, volume, remaining material — for reproducibility.

How Tirzepatide Works

Tirzepatide is a synthetic 39–amino acid peptide engineered to act as a dual agonist at two incretin receptors at once: GLP-1 and GIP, both of which contribute to glucose-dependent insulin secretion and appetite regulation. Its activity also suppresses glucagon, slows gastric emptying and reduces food intake. A fatty-acid moiety extends its half-life to roughly five days, which is what supports once-weekly dosing in trials. The balanced dual activity is what distinguishes it from single GLP-1 agonists in the comparative literature.

Reported Benefits & Side Effects

Benefits observed in trials

• Substantial HbA1c reductions in the Type 2 diabetes program, frequently exceeding active GLP-1 comparators.
• Marked weight loss — on the order of 11 kg more than a GLP-1 receptor agonist comparator over 26 weeks in head-to-head work, and roughly 20–21% at the top dose in the obesity study.
• Improvements in lipid profiles, blood pressure and waist circumference.
• A high proportion of high-dose participants reached clinically meaningful weight-loss thresholds.

Side effects reported

• Dose-dependent gastrointestinal effects — nausea, diarrhoea, vomiting and constipation — most common during escalation and usually mild to moderate.
• Occasional mild injection-site redness or irritation.
• Generally transient and mitigated by slower titration.

Supporting Lifestyle Factors (Research Context)

• Protein-forward, micronutrient-dense nutrition in the published study designs.
• Combined resistance and aerobic activity to preserve lean mass during weight reduction.
• Adequate sleep, stress management and hydration as standard trial controls.

Injection Technique (Reference Only)

• Prepare the vial and site with alcohol swabs and let them dry.
• Insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Split volume across sites when it exceeds a comfortable single injection, as at the high-dose steps.
• Rotate sites systematically and dispose of sharps in an approved container.

References

Related Protocols